Margins matter. The more Celgene (Nasdaq: CELG) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. That's why I check on my holdings' margins at least once a quarter. I'm looking for the absolute numbers, comparisons to sector peers and competitors, and any trend that may tell me how strong Celgene's competitive position could be.

Here's the current margin snapshot for Celgene and some of its sector and industry peers, and direct competitors.

Company

TTM Gross Margin

TTM Operating Margin

TTM Net Margin

 Celgene

92.6%

32.8%

27.8%

 Bristol-Myers Squibb (NYSE: BMY)

73.1%

28.5%

55%

 Amgen (Nasdaq: AMGN)

85.7%

38.3%

31.2%

 Merck (NYSE: MRK)

69.8%

23%

28.2%

 Biogen Idec (Nasdaq: BIIB)

91.5%

33.1%

23.9%

Source: Capital IQ, a division of Standard & Poor's. TTM = trailing 12 months.

Unfortunately, that chart doesn't tell us much about where Celgene has been or where it's going. A company with rising gross and operating margins often fuels its growth by increasing demand for its products. If it sells more units while keeping costs in check, its profitability increases. Conversely, a company with gross margins that inch downward over time is often losing out to competition, and possibly engaging in a race to the bottom on prices. If it can't make up for this problem by cutting costs -- and most companies can't -- then both the business and its shares face a decidedly bleak outlook.

Of course, over the short term, the kind of economic shocks we recently experienced can drastically affect a company's profitability. That's why I like to look at five fiscal years' worth of margins, along with the results for the trailing 12 months (TTM), the last fiscal year, and last fiscal quarter (LFQ). You can't always reach a hard conclusion about your company's health, but you can better understand what to expect, and what to watch.

Here's the margin picture for Celgene over the past few years.


(Because of seasonality in some businesses, the numbers for the last period on the right -- the TTM figures -- aren't always comparable to the FY results preceding them.)

Here's how the stats break down:

  • Over the past five years, gross margin peaked at 92% and averaged 88.7%. Operating margin peaked at 31.3% and averaged 21.9%. Net margin peaked at 28.9% and averaged (0.7%).
  • Fiscal year 2009 gross margin was 92%, 330 basis points better than the 5-year average. Fiscal year 2009 operating margin was 31.3%, 940 basis points better than the 5-year average. Fiscal year 2009 net margin was 28.9%, 2,960 basis points better than the 5-year average.
  • TTM gross margin is 92.6%, 390 basis points better than the 5-year average. TTM operating margin is 32.8%, 1,090 basis points better than the 5-year average. TTM net margin is 27.8%, 2,850 basis points better than the 5-year average.
  • LFQ gross margin is 92%, 10 basis points better than the prior year quarter. LFQ operating margin is 23.4%, 210 basis points worse than the prior year quarter. LFQ net margin is 18.2%, 450 basis points worse than the prior year quarter.

With recent 12-month-period operating margins exceeding historical averages, Celgene looks like it is doing fine.

If you take the time to read past the headlines and crack a filing now and then, you're probably ahead of 95% of the market's individual investors. By keeping an eye on the health of your companies' margins, you can spot potential trouble early, or figure out whether the numbers merit Mr. Market's enthusiasm or pessimism. Let us know what you think of the health of the margins at Celgene in the comments box below. Or, if you're itching to learn more, head on over to our quotes page to view the filings directly.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletters today, free for 30 days. The Motley Fool has a disclosure policy.